CLINICAL_TRIALS ClinicalTrials.gov record update

Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05114421
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:29.781776+00:00
Published At: 2025-08-07T00:00:00+00:00
Record Updated At: 2025-08-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High Grade Fallopian Tube Serous Adenocarcinoma", "High Grade Ovarian Serous Adenocarcinoma", "Peritoneal High Grade Serous Adenocarcinoma", "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent High Grade Ovarian Serous Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-07"
protocolSection.identificationModule.nctId: "NCT05114421"
protocolSection.identificationModule.officialTitle: "Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.